Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

There is a pressing need to identify new drug targets and novel approaches for treatment of non-small-cell lung carcinoma (NSCLC). Members of the epidermal growth factor receptor (EGFR) and Met receptor families have been identified as important molecular targets for NSCLC. Two EGFR tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, S, Zerillo, C, Kolmakova, J, Christensen, J G, Harris, L N, Rimm, D L, DiGiovanna, M P, Stern, D F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661782/
https://www.ncbi.nlm.nih.gov/pubmed/19240716
http://dx.doi.org/10.1038/sj.bjc.6604937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661782/
https://www.ncbi.nlm.nih.gov/pubmed/19240716
http://dx.doi.org/10.1038/sj.bjc.6604937

Ejemplares similares